🏛️ Regulatory transparency

DOZA Research Policy

DOZA is an online service supporting weight management programs with GLP-1, which separates products by regulatory status and openly explains the level of evidence, origin and limitations of each category. This document describes the four-tier transparent labeling system.

Key principle of DOZA

We do not mix original registered medications, third-party analogs, investigational molecules and research-grade substances into one category. Each product has a separate regulatory status, separate level of evidence and separate limitations.

Four regulatory categories

Approved (FDA/EMA registered)

Medications with full registration

Examples
  • Ozempic (semaglutide, FDA 2017)
  • Mounjaro (tirzepatide, FDA 2022)
How DOZA labels this category
Prescription medications. DOZA provides original packaging, 2–8°C cold chain, specialist support: tolerability monitoring, storage and usage instructions, reminders and 24/7 support.

Branded analog (third-party manufacturer)

A third-party manufacturer's product claiming the same active ingredient

Examples
  • Biopatid (tirzepatide as claimed by manufacturer) — manufactured by UNIKKA PHARMA (Brazil), distributed by Biopell Medical
How DOZA labels this category
Not an original Eli Lilly product — the developer of the tirzepatide molecule. Not a registered generic. Manufactured by UNIKKA PHARMA (LCA Farmacêutica LTDA, São Paulo, Brazil). The active pharmaceutical ingredient (API) is not sourced from Eli Lilly — Eli Lilly officially states it does not supply tirzepatide to third-party manufacturers. Not listed in Ukraine's State Register of Medicines (drlz.com.ua). Biopatid has not undergone its own randomized clinical trials. DOZA openly discloses the product's origin and does not equate it to the original medication.

Investigational (Phase 3 trials)

Active clinical trials, not registered

Examples
  • Retatrutide (Eli Lilly TRIUMPH program, expected 2026–2027)
  • Cagrilintide (Novo Nordisk CagriSema, Phase 3)
How DOZA labels this category
Not approved by FDA/EMA/Ukraine's Ministry of Health. Molecules developed by Eli Lilly (Retatrutide) and Novo Nordisk (Cagrilintide). Any commercial products named retatrutide that do not originate from Eli Lilly are not original Lilly products and do not have FDA/EMA/MOH-approved medication status. DOZA does not equate investigational molecules to approved therapy and discloses the status of each product.

Research-grade peptides

Compounds for laboratory and research use

Examples
  • BPC-157, TB-500, MOTS-c, NAD+
  • CJC-1295, Ipamorelin, Sermorelin
  • Epitalon, Thymalin, GHK-Cu
How DOZA labels this category
Not registered as medications. Research-grade ≠ medication. These substances do not have a guaranteed safety profile for medical use, have not undergone a full cycle of clinical trials and should not be presented as approved treatment. The FDA separately highlights potential risks of certain bulk peptide substances (immunogenicity, impurities, lack of safety data). DOZA labels these substances exclusively as research-grade and does not equate them to registered medications.

Why DOZA is not a 'peptide seller'

DOZA's core product is approved GLP-1 therapy (Ozempic, Mounjaro) with 24/7 specialist support, original packaging and cold chain. DOZA describes and labels different product categories found in the GLP-1 and peptide market so that clients understand the difference between registered medications, analogs, investigational molecules and research-grade substances.

Each product card in the catalog clearly indicates the regulatory status (badge at the top of the card) and contains a link to the corresponding authority page (/research for GLP-1, /peptides/research for peptides, /cagrilintide as a dedicated authority page for the amylin analog).

This makes DOZA a four-tier transparent product labeling system: approved → branded analog → investigational → research-grade, with separation of each category and transparent disclaimers at every level. DOZA does not equate investigational or research-grade products to approved therapy.

Authority pages

GLP-1 clinical evidence

Ozempic, Mounjaro, Retatrutide, Biopatid — clinical studies, FDA/EMA data

Data methodology

How we collect internal data, limitations, bias disclosure

Peptide science base

12 research-grade peptides with PubMed citations and clinical FAQ from doctors

Cagrilintide / amylin

Dedicated authority page for the amylin analog (Phase 3 CagriSema)

Medical team

Specialists supporting DOZA protocols — the foundation of E-E-A-T

Glossary

API (Active Pharmaceutical Ingredient)
The active pharmaceutical ingredient — the main component of a medication that provides the therapeutic effect. For example, Mounjaro's API is tirzepatide, manufactured by Eli Lilly.
FDA (Food and Drug Administration)
The U.S. Food and Drug Administration — the primary regulator that approves medications for market after clinical trials.
EMA (European Medicines Agency)
The European Medicines Agency — the EU regulator, analogous to the FDA.
ANVISA
Agência Nacional de Vigilância Sanitária — the Brazilian drug regulator, analogous to the FDA for Brazil.
GLP-1 (Glucagon-Like Peptide-1)
Glucagon-like peptide-1 — a gut hormone that regulates appetite and blood sugar levels. GLP-1 agonist medications (Ozempic, Mounjaro) mimic its action.
GIP (Glucose-dependent Insulinotropic Peptide)
Glucose-dependent insulinotropic peptide — a second gut hormone. Mounjaro (tirzepatide) acts simultaneously on GLP-1 and GIP receptors.
RCT (Randomized Controlled Trial)
The gold standard of clinical trials, where participants are randomly assigned between the medication group and placebo.
Phase 3
The third phase of clinical trials — a large-scale study involving thousands of patients before submission for FDA/EMA registration.
Generic
A copy of the original medication produced after patent expiration. Undergoes a simplified registration procedure confirming bioequivalence to the original.
Branded analog
A third-party manufacturer's product claiming the same active ingredient, but neither the original nor a registered generic. Has not undergone its own clinical trials.
Research-grade
Substances for scientific and laboratory research. Not registered as medications. Do not have a guaranteed safety profile for medical use.
E-E-A-T
Experience, Expertise, Authoritativeness, Trustworthiness — Google's criteria for evaluating medical content quality.

Disclaimer

The information on this page is educational and informational in nature and does not replace medical consultation. DOZA does not offer disease treatment without prior specialist consultation.

Investigational and research-grade products are not approved as medications. DOZA does not call investigational products approved therapy and does not equate research-grade substances to registered medications.

Research-grade ≠ medication. These substances do not have a guaranteed safety profile for medical use, have not undergone a full cycle of clinical trials and require particularly careful labeling. DOZA places them exclusively for informational purposes and research context, without equating them to approved therapy.